New York, January 07, 2022 (GLOBE NEWSWIRE) – Reportlinker.com announces the publication of the report “Hematuria Treatment Market Forecast to 2028 – COVID-19 Impact and Global Analysis by Treatment, Indication, Type and User final and geography “- https://www.reportlinker.com/p06195600/?utm_source=GNW
However, the undiagnosed cases of related indications affect the effectiveness of hematuria treatments thus hampering the market growth. The hematuria treatment market in Asia-Pacific is experiencing significant growth. Restrictions imposed by governments to contain the spread of COVID-19 have had an impact on ongoing clinical research. However, with the gradual easing of these restrictions, research activity is gaining momentum, which is expected to drive demand for hematuria treatment in the years to come.
On the basis of treatment, the hematuria treatment market is segmented into drugs, therapies, and others. The drugs and therapies segment is expected to represent the largest market share in 2020.
It is further expected to register the highest CAGR in the market during the period 2020-2028. Based on the indications, the Hematuria Treatment market is segmented into Urinary Tract Infections, Kidney Stones, Urethritis, Blood Cancer, Bladder Stones, Prostate Cancer, Cystitis, Trauma, Vigorous Exercise, Polycystic Disease kidneys, endometriosis and menstruation.
Urinary tract infections segment dominated the market in 2020 with a share of 17.31%, and it is expected to maintain its dominance during the forecast period. Based on type, the hematuria treatment market is segmented into gross hematuria, microscopic hematuria, idiopathic hematuria, and jogger hematuria. The microscopic hematuria segment is believed to hold the largest market share in 2021. The gross hematuria segment market is expected to grow at a CAGR of 2.6% during the forecast period. On the basis of end use, the hematuria treatment market is further segmented into hospitals, clinics, ASCs, and others. Hospital segment dominated the market in 2020 with a share of 36.52%, and it is expected to maintain its dominance during the forecast period.
The World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC) and the International Society for the Application of Stem Cells were among the primary and secondary sources mentioned in the preparation of the report on the hematuria treatment market.
Read the full report: https://www.reportlinker.com/p06195600/?utm_source=GNW
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.